Women and men in tropical dry forests: a preliminary review

From a broad review of 670 publications on gender and forests, ~130 were found to address the world’s dry forests. These were examined with the intent to extract gendered social, cultural, political and economic patterns of relevance in such forests. Seven interrelated themes recurred in this literature: 1) population pressure, 2) migration, 3) intra-familial and inter-group conflict, 4) hierarchy and significant power differences, 5) strict gender differentiation, 6) commercialization of crops and NTFPs, and 7) fuelwood collection. Based upon these themes, the uniqueness of each situation and the importance of finetuning any approach to local realities to generate outcomes that can benefit women, we propose four promising ways to enhance the prospects for gender equity in dry forest areas: 1) a strengthening of groups and collective action, 2) explicit challenges to traditional gender norms, 3) a focus on products and spaces that interest women, and 4) addressing migration and population issues

A third dimension in the mirror? How senior managers design products and organizations

Individual CEO characteristics may affect architectural choices through the application of managerial discretion. Systems such as organizations and their products are not purely driven toward modularity because of external forces. Individual CEO characteristics may constitute an additional dimension to established mirroring considerations that impacts both the choice of architecture and the correspondence between product and organization architectures

Working towards an engagement turn to agricultural research in the Tonle Sap Biosphere,Cambodia

A new generation of agricultural research programs are embracing use of participation as a vehicle for achieving greater impact and supporting transformative change in complex social-ecological systems. In this paper, we share learning from use of participatory action research in the Tonle Sap biosphere in Cambodia, as the main implementing methodology within a large multi-partner agricultural research program. We describe the program’s espoused approach to applying participatory methodologies focusing on co-ownership, equity and reflexivity with stakeholders throughout the research process. We then reflect upon our practice as we pursued initiatives to support increased income and nutrition outcomes for the poorest people in a diverse aquatic agricultural system characterized by inequality. We discuss the challenges and early successes of the process and share three enabling conditions that support a shift towards quality of participation in agricultural research: (1) focusing at the outset on a strengthsbased mind-set, (2) staging a critical stance to progressively build equity in process and outcomes, and (3) institutionalizing reflexivity to facilitate ongoing learning

THE ROLE OF INTERDEPENDENCE IN THE MICRO-FOUNDATIONS OF ORGANIZATION DESIGN: TASK, GOAL, AND KNOWLEDGE INTERDEPENDENCE

Interdependence is a core concept in organization design, yet one that has remained consistently understudied. Current notions of interdependence remain rooted in seminal works, produced at a time when managers’ near-perfect understanding of the task at hand drove the organization design process. In this context, task interdependence was rightly assumed to be exogenously determined by characteristics of the work and the technology. We no longer live in that world, yet our view of interdependence has remained exceedingly task-centric and our treatment of interdependence overly deterministic. As organizations face increasingly unpredictable workstreams and workers co-design the organization alongside managers, our field requires a more comprehensive toolbox that incorporates aspects of agent-based interdependence. In this paper, we synthesize research in organization design, organizational behavior, and other related literatures to examine three types of interdependence that characterize organizations’ workflows: task, goal, and knowledge interdependence. We offer clear definitions for each construct, analyze how each arises endogenously in the design process, explore their interrelations, and pose questions to guide future research

Long-term follow-up of patients with previous myocarditis using radionuclide ventriculography

A prospective long-term follow-up study is reported of 18 of 19 patients who survived a bout of presumed myocarditis 6–136 months (average 54 months) previously. The study included 14 males and four females, ranging from 27 to 63 years of age (mean, 44 years). Chest X-ray, ECG, echocardiogram, and resting and exercise radionuclide ventricular ejection fraction (RNVEF) for assessment of ventricular function were evaluated at follow-up. Resting and exercise RNVEF from seven control subjects were evaluated for comparison. Residual abnormalities were noted in chest X-ray (16%), echocardiogram (30%), and ECG (55%) in these predominantly asymptomatic patients (17/18 or 95%). The resting RNVEF (mean ±SD) for the myocarditis group versus controls were 0.57±0.1 and 0.65±0.1 ( P =NS), respectively. The exercise RNVED for the myocarditis group versus controls were 0.56±0.1 and 0.74±0.05 ( P <0.01), respectively. Abnormal resting RNVEF was noted in six (33%) and exercise RNVEF in 14 (77%) patients in the myocarditis group. Two patients with abnormal exercise RNVEF subsequently developed findings consistent with dilated cardiomyopathy. It is unclear as to whether the abnormal ventricular function may serve as a marker for future development of dilated cardiomyopathy.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/41583/1/380_2005_Article_BF02072391.pd

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF)

&lt;p&gt;Aims: This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.&lt;/p&gt; &lt;p&gt;Methods and results: Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate &#60;60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L.&lt;/p&gt; &lt;p&gt;Conclusion: The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.&lt;/p&gt